Personal Health Record Software for Neuroendocrine Tumors: Patient-Centered Design Approach

Journals

1. O’Rorke M, Xu T, DeCook R, McDowell B, Gryzlak B, Rudzianski N, Serrano K, Wehrheim A, Grewal U, Chandrasekharan C, Dillon J, Halfdanarson T, Gamblin T, Cowell L, Else T, Soares H, Sukrithan V, Chandaka S, Sanoff H, He F, Geller D, Ramirez R, Liu M, Lancaster W, Mailman J, Moran H, Wahmann M, Gellerman E, Chrischilles E, Chamberlain A, Cerda V, Early C, Gryzlak B, Hamilton H, Hourcade J, Indrees K, Kazmi S, Hughes A, McDowell B, O’Dell A, O’Rorke M, Ramnaraign B, Roller L, Taylor B, Tepper M, West K, Zamba G. Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort. JNCI: Journal of the National Cancer Institute 2026 View
2. O’Rorke M, McDowell B, Xu T, DeCook R, Gryzlak B, Rudzianski N, Serrano K, Wehrheim A, Grewal U, Chandrasekharan C, Dillon J, Halfdanarson T, Schnell M, Witter C, Gamblin T, Kazmi S, Cowell L, Else T, Soares H, Sukrithan V, Chandaka S, Sanoff H, He F, Geller D, Ramirez R, Liu M, Lancaster W, Mailman J, Moran H, Wahmann M, Gellerman E, Chrischilles E. Assessing Patient Characteristics in Neuroendocrine Tumor Research: A Comparison of the NET-PRO Study to SEER Population-Based Data. Endocrine 2026;91(1) View
3. Hu P, Yan L, Xue B, He N, Qian J, Lu X, Liu M, Xu Y, Han X, Ye M, Tang Q. A Novel Bruton’s Tyrosine Kinase Inhibitor Suppresses Pancreatic Neuroendocrine Neoplasms Progression via ATF3-Induced Ferroptosis. Cancers 2026;18(14):2277 View
4. O’Rorke M, Gryzlak B, Xu T, McDowell B, DeCook R, Rudzianski N, Serrano K, Wehrheim A, Grewal U, Chandrasekharan C, Dillon J, Halfdanarson T, Schnell M, Witter C, Gamblin T, Kazmi S, Cowell L, Else T, Soares H, Sukrithan V, Chandaka S, Sanoff H, He F, Geller D, Ramirez R, Liu M, Lancaster W, Mailman J, Moran H, Wahmann M, Gellerman E, Chrischilles E. Using a participation monitoring database to enhance recruitment in a rare cancer population. Journal of Clinical and Translational Science 2026;10(1) View